key: cord-0807092-9j6z5wjr
authors: Berbert Ferreira, S.; Gavazzoni Dias, M.F.R.; Berbert Ferreira, R.; Neves Neto, A.C.; Trüeb, R.M.; Lupi, O.
title: Rapidly progressive alopecia areata totalis in a COVID‐19 patient, unresponsive to tofacitinib
date: 2021-03-20
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.17170
sha: bfc987265171f1d7b318bfeac6237595fe087a01
doc_id: 807092
cord_uid: 9j6z5wjr

Alopecia areata (AA) is a common autoimmune disease characterized by non-scarring hair loss. (1) Tofacitinib is an effective oral JAK 1/3 inhibitor that can block IL-2, IL-7 and IL-6 and is reported as an option for alopecia areata treatment.(2,3) Though some JAK inhibitors are possible new treatments for severe acute respiratory syndrome coronavirus disease, no treatment of Covid-19 with tofacitinib has been reported to date and the withdrawal of the drug in patients with alopecia areata that become infected with the virus, is controversial.

Dear Editor, Alopecia areata (AA) is a common autoimmune disease characterized by non-scarring hair loss. 1 Tofacitinib is an effective oral JAK 1/3 inhibitor that can block IL-2, IL-7 and IL-6 and is reported as an option for alopecia areata treatment. 2,3 Though some JAK inhibitors are possible new treatments for severe acute respiratory syndrome coronavirus disease, no treatment of COVID-19 with tofacitinib has been reported to date and the withdrawal of the drug in patients with alopecia areata that become infected with the virus is controversial. 4 We report a 24-year-old female patient with alopecia areata totalis (AAT) who tested positive for COVID-19 while using tofacitinib 5 mg BID during the last 12 months. Prior to the infection, she had a complete hair regrowth with no signs of disease activity. The patient presented with anosmia and ageusia and was tested positive for SARS-CoV-2 (COVID-19) polymerase chain reaction. Tofacitinib was discontinued for 14 days when she developed a sudden intense anagen effluvium. Tofacitinib was restarted at the 15th day, at the same dose, without any improvement of the anagen effluvium after 3 months (Figs 1  and 2 ).

The worsening of the alopecia areata lesions and reactivation of the disease could be due to the sudden suspension of the drug, but the unresponsiveness to the reintroduction of tofacitinib points out to a possible direct effect of the virus towards the hair follicle. The role of COVID-19 in postinfection hair shed is unknown since only few cases of AA and early onset of telogen effluvium have been reported. [6] [7] [8] The secretion of granzymes, perforins, granulysin and Fas ligand, which trigger programmed cell death, are common pathways involved in both viruses and alopecia areata inflammation. 5 COVID-19 could break the hair follicle immune privilege and activate CD8 + cytotoxic cells and increase the secretion of IFN gamma, leading to an extensive immune response and cell disruption. An anagen effluvium during COVID-19 infection may represent a possible mechanism of the virus towards the hair follicle, as described in dengue (DENV). DENV is capable of causing a direct injury to the hair follicle leading to inflammation and cell death. [6] [7] [8] Alopecia areata cases seem to have increased during the pandemic, but it is not clear whether this estimative is due to the psychological stress of the quarantine conditions or to subclinical infection of COVID-19. [8] [9] [10] The continuous use of the JAK inhibitors in AA patients who develop COVID-19 infection is still controversial.

This case report demonstrates that, in patients with AA and COVID-19, the withdrawal of tofacitinib may lead to a persistent unresponsive anagen effluvium. The real effect of COVID-19 to hair follicle is still unclear, but the reactivation of the AA during COVID-19 infection may represent a possible mechanism of the virus towards the hair follicle immune privilege.

We recommend testing all patients with anagen or telogen effluvium, for COVID-19.

Alopecia areata: a comprehensive review of pathogenesis and management

An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: a case report and a review of the literature

Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis

HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19

The CD8 T cell response to respiratory virus infections

Dengue virus infects primary human hair follicle dermal papilla cells

Dengue-associated telogen effluvium: a report of 14 patients

Evaluation of the effects of COVID-19 pandemic on hair diseases through a web-based questionnaire

Short-term stress-related increasing cases of alopecia areata during the COVID-19 pandemic

What can the hair tell us about COVID-19?